Key finding
FBS decreased significantly in the sitagliptin + metformin group compared to metformin alone (P = 0.030).
This study evaluated the effects of sitagliptin plus metformin therapy on metabolic profiles in patients with type 2 diabetes and NAFLD, finding significant improvements in various metabolic markers.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Quick read
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Sitagliptin + Metformin, Metformin
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Fasting Blood Sugar (FBS)
Comparator
Metformin
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effects of sitagliptin plus metformin therapy on metabolic profiles in patients with type 2 diabetes and NAFLD, finding significant improvements in various metabolic markers.
The findings highlight the potential of combining sitagliptin with metformin to improve metabolic health in patients suffering from both type 2 diabetes and NAFLD. Given the rising prevalence of these conditions, effective treatment strategies are crucial for reducing long-term complications and improving patient outcomes.
The study's sample size may limit the generalizability of the findings. The duration of the intervention may not reflect long-term effects. Potential confounding factors were not fully controlled.
Published in
Publication details and source links for this paper.
Habib Y, Majid R, Niki K, Majid M, Narges ST. Sitagliptin Plus Metformin Therapy Improves Metabolic Profile in Patients with Type 2 Diabetes and NAFLD. Current Therapeutic Research, Clinical and Experimental. 2024;101:100764. doi:10.1016/j.curtheres.2024.100764
Save this study and add notes to your research library.
Fasting blood sugar decreased by 18 mg/dL in the sitagliptin + metformin group (P = 0.030).
Total cholesterol decreased by 58 mg/dL in the sitagliptin + metformin group (P = 0.017).
Triglycerides decreased by 93 mg/dL in the sitagliptin + metformin group (P = 0.008).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors, Metformin and Alanine Aminotransferase (ALT), Fasting blood sugar (FBS), Glycemia risk index, and 3 more.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
12
Evidence pairs
262
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
The primary outcomes reported in this study.
Dipeptidyl peptidase-4 inhibitors → Alanine Aminotransferase (ALT)
Dipeptidyl peptidase-4 inhibitors → Alanine Aminotransferase (ALT)
Evidence profile
Dipeptidyl peptidase-4 inhibitors → Fasting blood sugar (FBS)
Dipeptidyl peptidase-4 inhibitors → Fasting blood sugar (FBS)
Evidence profile
Dipeptidyl peptidase-4 inhibitors → Glycemia risk index
Dipeptidyl peptidase-4 inhibitors → Glycemia risk index
Evidence profile
Dipeptidyl peptidase-4 inhibitors → Serum vitamin D3 levels (Placebo)
Dipeptidyl peptidase-4 inhibitors → Serum vitamin D3 levels (Placebo)
Evidence profile
Dipeptidyl peptidase-4 inhibitors → Total cholesterol
Dipeptidyl peptidase-4 inhibitors → Total cholesterol
Evidence profile
Dipeptidyl peptidase-4 inhibitors → Triglycerides
Dipeptidyl peptidase-4 inhibitors → Triglycerides
Evidence profile
Metformin → Alanine Aminotransferase (ALT)
Metformin → Alanine Aminotransferase (ALT)
Evidence profile
Metformin → Fasting blood sugar (FBS)
Metformin → Fasting blood sugar (FBS)
Evidence profile
Metformin → Glycemia risk index
Metformin → Glycemia risk index
Evidence profile
Metformin → Serum vitamin D3 levels (Placebo)
Metformin → Serum vitamin D3 levels (Placebo)
Evidence profile
Metformin → Total cholesterol
Metformin → Total cholesterol
Evidence profile
Metformin → Triglycerides
Metformin → Triglycerides
Evidence profile
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and Adipokine and Angiogenic Markers, DPP-4 Inhibitors and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies on DPP-4 Inhibitors
Contributes to DPP-4 Inhibitors evidence base.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
DPP-4 Inhibitors appears to improve Adipokine and Angiogenic Markers.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Alanine Aminotransferase (ALT)
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Triglycerides
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
DPP-4 Inhibitors appears to improve CGM Time in Range.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glycemia risk index
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Metformin Therapies appears to improve Fasting Glucose.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Limited | EvidenceScore™ 34.2 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
DPP-4 Inhibitors appears to improve Fasting Glucose.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
